Pannathat Soontrapa

anti-cN1a antibody anti-cytosolic 5′-nucleotidase 1 A antibody CK creatine kinase ENMC European Neuromuscular Center GSEA gene set enrichment analysis IBM inclusion body myositis IFN interferon IQR interquartile range IVIG intravenous immunoglobulin KLRG1 killer cell lectin-like receptor G1 MRC Medical Research Council mRS Modified Rankin Scale PD-1 programmed cell death 1 RNAseq RNA sequencing TGF-β transforming growth factor-beta T-LGLL T-cell large granular lymphocytic leukemia TMM Trimmed...

Pannathat Soontrapa, MD and Peter Goadsby, MD, PhD, DSc, reviewing A case-crossover analysis supports previous suggestions of a risk. To investigate whether triptans are definitely contraindicated in patients with cardiovascular risk factors, researchers conducted a nationwide study comprising all triptan-prescribed patients in Denmark from January 1995 to August 2022.

INTRODUCTION Creatine kinase (CK) is a muscle enzyme involved in the phosphocreatine circuit for energy supply of muscles [1], whilst aldolase is a glycolytic enzyme abundantly expressed in not only muscles but also liver, brain and red blood cells [2]. Elevation of serum CK (hyperCKemia) and aldolase level is considered a biomarker of muscle damage secondary to a leakage of these cytosolic enzymes into the bloodstream [3]. HyperCKemia is often accompanied by high aldolase level [4, 5].